Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 8/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35211364 | 1.00 | NR4A2 (0.46) | NR4A2NOTUMMAP2K1BRD4MAP2K2 | |
| SCHEMBL22790397 | 0.84 | MAP2K1 (0.45) | MAP2K1MAP2K2MEN1ALDH1A1HPGD | |
| SCHEMBL35210953 | 0.84 | MAP2K1 (0.45) | MAP2K1MAP2K2MEN1ALDH1A1HPGD | |
| SCHEMBL35210704 | 0.82 | NOTUM (0.37) | NR4A2NOTUMALDH1A1KMT2A | |
| SCHEMBL26691558 | 0.80 | NR4A2 (0.46) | NR4A2MAP2K1BRD4MEN1ALDH1A1 | |
| SCHEMBL12180225 | 0.78 | NR4A2 (0.43) | NR4A2NOTUMBRD4MEN1ALDH1A1 | |
| SCHEMBL24330123 | 0.75 | ALDH1A1 (0.42) | NR4A2BRD4ALDH1A1 | |
| SCHEMBL24330126 | 0.75 | NR4A2 (0.43) | NR4A2BRD4ALDH1A1LMNAKMT2A | |
| SCHEMBL22790101 | 0.75 | KDM4E (0.42) | NR4A2BRD4MEN1ALDH1A1LMNA | |
| SCHEMBL35210583 | 0.75 | NR4A2 (0.39) | NR4A2BRD4MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | INCYTE CORP (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2020249064-A1 | COMPOUNDS FOR MODULATING FXR | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | CDK4, CCNA1, CCNO | NR4A2 179/4885NOTUM 4746/4885MAP2K1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.